Last reviewed · How we verify
Infanrix®-IPV+Hib and Prevenar®
This is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and pneumococcal disease.
This is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and pneumococcal disease. Used for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children, Active immunization against invasive pneumococcal disease caused by Streptococcus pneumoniae in infants and children.
At a glance
| Generic name | Infanrix®-IPV+Hib and Prevenar® |
|---|---|
| Also known as | Infanrix®-IPV+Hib: DTap, IPV and adsorbed conjugated Hib, Prevenar®: Pneumococcal saccharide conj vaccine, adsorbed. |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Infanrix-IPV+Hib is a pentavalent vaccine containing inactivated toxoids and antigens that trigger adaptive immune responses, while Prevenar is a pneumococcal conjugate vaccine. Together they provide active immunization against multiple bacterial pathogens by inducing humoral and cellular immunity in infants and young children.
Approved indications
- Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children
- Active immunization against invasive pneumococcal disease caused by Streptococcus pneumoniae in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (PHASE3)
- A Study of the Interaction Between BCG And MenC Immunisation: BAM (PHASE4)
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine (PHASE2)
- Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (PHASE2)
- Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age (NA)
- Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infanrix®-IPV+Hib and Prevenar® CI brief — competitive landscape report
- Infanrix®-IPV+Hib and Prevenar® updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI